AB0821 Evolution of The Values of Alkaline Phosphatase (ALP) in Patients Treated with Zoledronic Acid and Diagnosed with The Paget's Disease of Bone

2016 ◽  
Vol 75 (Suppl 2) ◽  
pp. 1184.2-1184 ◽  
Author(s):  
M. Retuerto ◽  
L. Sierra ◽  
M. Martín ◽  
C. Moriano ◽  
A. García ◽  
...  
Keyword(s):  
Alkaline Phosphatase ◽  
Zoledronic Acid ◽  
Paget’S Disease ◽  
Paget's Disease ◽  
Paget’S Disease Of Bone ◽  
Paget's Disease Of Bone

Pharmacotherapy of Paget's Disease of Bone: Focus on Zoledronic Acid

2009 ◽  
Vol 1 ◽  
pp. CMT.S1095
Author(s):  
Konstantinos Tziomalos ◽  
Vasilios G. Athyros ◽  
Asterios Karagiannis
Keyword(s):  
Zoledronic Acid ◽  
Serum Alkaline Phosphatase ◽  
Paget’S Disease ◽  
Paget's Disease ◽  
Paget’S Disease Of Bone ◽  
Principal Characteristic ◽  
Paget's Disease Of Bone ◽  
Osteoclastic Activity ◽  
Therapeutic Decisions ◽  
Increased Risk

Paget's disease of bone (PDB) affects 1%-3% of the population and is associated with increased risk for bone fracture and deformity. Increased osteoclastic activity is the principal characteristic of PDB. Bisphosphonates inhibit osteoclastic activity and represent the mainstay of treatment of PDB. Zoledronic acid, a potent member of this class, normalizes serum alkaline phosphatase (ALP) levels in the majority of patients with PDB and induces sustained disease remissions. It appears to be more effective than both risedronate and pamidronate. However, it is not clear whether bisphosphonates, including zoledronic acid, improve the clinical outcome of patients with PDB. Zoledronic acid was associated with increased risk for atrial fibrillation and osteonecrosis of the jaw in some studies in patients with osteoporosis and cancer, respectively, but not in patients with PDB. Until we have data on the effects of bisphosphonates on clinical outcomes in PDB such as fracture, deformity and osteosarcoma, we must base therapeutic decisions on the data regarding the effects of these agents on disease activity markers (such as serum ALP levels) and bone pain.

Plasma Calcitonin in Paget's Disease of Bone

1977 ◽  
Vol 52 (3) ◽  
pp. 329-332 ◽  
Author(s):  
J. A. Kanis ◽  
G. Heynen ◽  
R. J. Walton
Keyword(s):  
Alkaline Phosphatase ◽  
Plasma Levels ◽  
Paget’S Disease ◽  
Paget's Disease ◽  
Paget’S Disease Of Bone ◽  
Paget's Disease Of Bone ◽  
Control Subjects ◽  
Plasma Alkaline Phosphatase ◽  
And Control ◽  
Age And Sex

1. Plasma levels of immunoreactive calcitonin were measured in 22 patients with untreated Paget's disease of bone and in 22 control subjects matched for age and sex. 2. No significant differences in plasma calcitonin were found between patients and control subjects, and hormone levels did not correlate significantly with activity of plasma alkaline phosphatase. 3. These results suggest that Paget's disease of bone is not due to deficient secretion of endogenous calcitonin.

scholarly journals Response to zoledronic acid in patients with active Paget's disease of bone: A retrospective study

2019 ◽  
Vol 23 (1) ◽  
pp. 117 ◽  
Author(s):  
Sadishkumar Kamalanathan ◽  
Harsh Durgia ◽  
Jayaprakash Sahoo ◽  
Rajan Palui ◽  
Ritesh Kumar ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Zoledronic Acid ◽  
Paget’S Disease ◽  
Paget's Disease ◽  
Paget’S Disease Of Bone ◽  
Paget's Disease Of Bone

Scintigraphic, biochemical, and clinical response to zoledronic acid treatment in patients with Paget’s disease of bone

2008 ◽  
Vol 26 (6) ◽  
pp. 635-641 ◽  
Author(s):  
Avraam Avramidis ◽  
Stergios A. Polyzos ◽  
Efstratios Moralidis ◽  
Georgios Arsos ◽  
Zoe Efstathiadou ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Clinical Response ◽  
Acid Treatment ◽  
Paget’S Disease ◽  
Paget's Disease ◽  
Paget’S Disease Of Bone ◽  
Paget's Disease Of Bone

scholarly journals Re-treatment of relapsed Paget's disease of bone with zoledronic acid: results from an open-label study

2013 ◽  
Vol 2 ◽  
Author(s):  
Ian R Reid ◽  
Jacques P Brown ◽  
Naomi Levitt ◽  
José A Román Ivorra ◽  
Javier Bachiller-Corral ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Paget’S Disease ◽  
Paget's Disease ◽  
Paget’S Disease Of Bone ◽  
Paget's Disease Of Bone ◽  
Open Label ◽  
Open Label Study ◽  
Label Study

The effect of zoledronic acid on serum Dickkopf-1, osteoprotegerin and rankl in patients with paget's disease of bone

Bone ◽  
2009 ◽  
Vol 44 ◽  
pp. S289 ◽  
Author(s):  
S.A. Polyzos ◽  
A.D. Anastasilakis ◽  
Z. Efstathiadou ◽  
M. Kita ◽  
I. Litsas ◽  
...  
Keyword(s):  
Zoledronic Acid ◽  
Paget’S Disease ◽  
Paget's Disease ◽  
Paget’S Disease Of Bone ◽  
Paget's Disease Of Bone ◽  
Dickkopf 1
Sign in / Sign up

Export Citation Format

Share Document